LL-37 Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 4 to 12 weeks on-cycle, with 2 to 4 weeks off; CIRS-related protocols may run longer under clinical supervision
• Frequency: Once daily subcutaneous injection; a 5-days-on, 2-days-off schedule is a common alternative
• Common delivery routes: Subcutaneous injection (primary route for systemic goals); topical application (strongest clinical data for wound healing)
• Key timing notes: Morning administration is preferred to align with immune circadian rhythms; consistent daily timing matters more than the precise clock hour

Who This Protocol Is For

LL-37 sits in a different category from most peptides people run for performance or body composition goals. It is a naturally occurring antimicrobial peptide, part of the cathelicidin family (the class of peptides the body produces as a first-line immune defense), stored in neutrophils (a type of white blood cell) and deployed as part of innate immune defense. People who look into an LL-37 protocol are typically dealing with something the immune system is already struggling to handle, not looking for a performance edge.

The most common reasons someone investigates this protocol include chronic gut issues like SIBO. LL-37's ability to disrupt bacterial biofilms and support gut barrier integrity makes it relevant in that context. Chronic Inflammatory Response Syndrome (CIRS) is another primary use case, typically under direct practitioner supervision with longer cycle durations. Lyme disease support, general immune modulation, and wound healing round out the common applications, though the evidence quality varies considerably across these areas.

Experience level matters here more than it does with most research peptides. LL-37 triggers real immune activity, which means its effects are not subtle and its side effects are not trivial. People with a prior background in peptide protocols, especially immune-modulating ones, are better positioned to recognize how their body is responding and to adjust accordingly. Conservative start doses and close self-monitoring are standard practice for first-time LL-37 users.

Delivery method preference also shapes the protocol significantly. Topical application has the strongest clinical backing, particularly for wound healing, with a more defined evidence base than the injectable route. Subcutaneous injection is the primary route for systemic goals like gut health and immune modulation.

Anyone with an active malignancy, particularly breast, ovarian, or lung cancer, should not run LL-37. Its pro-tumorigenic activity in those cancer contexts is a hard stop. The same applies to anyone with a systemic autoimmune condition or who is pregnant or breastfeeding. This is not a peptide to approach casually, and it is not a protocol that belongs outside of practitioner oversight for most people considering it.

How Is an LL-37 Cycle Structured?

An LL-37 cycle does not follow the clean loading-then-steady-maintenance shape that many other peptides use. The defining structural feature is gradual titration: the dose starts conservatively and rises incrementally across the first several weeks until it reaches the level that produces a noticeable immune effect for the goal. Think of it less like filling a tank to a set level and more like slowly turning up a dial while monitoring how the system responds.

The on-cycle period typically runs somewhere between 4 and 12 weeks, depending on the goal. Acute applications, such as addressing an active infection or a wound healing need, tend toward the shorter end of that range. Protocols aimed at chronic conditions like CIRS or ongoing gut pathogen management tend toward the longer end, and in some supervised clinical contexts they extend further still. After the on-cycle period, a break of 2 to 4 weeks is standard practice, designed to prevent the immune system from becoming desensitized to the peptide's activity.

Three broad structural variants show up across protocols. The most widely referenced is the gradual titration approach, where the dose increases by a fixed increment each week across the cycle. A second variant uses a fixed dose through a block of weeks, followed by a washout period, then another dose block. A third approach, more common in physician-supervised settings, uses a lower frequency of administration across a longer timeframe rather than daily dosing. The full mechanics of each phase are covered in the Loading and Maintenance Phases section.

How Your Dose Is Determined

Because LL-37 directly activates immune pathways, the factors that determine the right dose are more consequential than with most peptides. There is no single starting point that works across all goals and all people, which is why titration is the structural feature of this protocol rather than an option.

What moves an LL-37 dose:

• Your goal: Acute applications like active infection support or wound healing tend to sit at the lower end of the range and often involve shorter cycles. Chronic conditions like CIRS or gut pathogen management may trend toward the higher end of the range over the course of a longer cycle, reached gradually through titration. Topical wound healing protocols operate within a different concentration framework entirely from injectable systemic use.
• Experience level: Someone with prior experience running immune-modulating peptides, with a clear sense of how their body signals overactivation, is better equipped to titrate upward than someone running their first immune-focused protocol. Beginners consistently land toward the conservative start of the range and advance more slowly, if at all.
• Delivery route: Subcutaneous injection is the primary route for systemic goals and calls for a careful titration approach given that the peptide reaches the bloodstream directly. Topical application for wound healing operates at a defined concentration range in the clinical literature and is administered locally rather than systemically, changing the risk profile substantially. These two routes are not interchangeable in dose logic.
• Individual response: LL-37's mechanism involves cytokine release (the signaling proteins that coordinate immune cell activity) and immune cell recruitment, and different people trigger that cascade with different intensity at the same dose. Some experience a Herxheimer-type reaction (a temporary worsening of symptoms as pathogens or biofilms break down) as the compound does its work; others do not. Where someone lands on the effective level is partly determined by how their immune system responds during titration, which is why the dose is not set in advance but discovered through the process.

Two additional factors shape the dose in ways specific to LL-37. First, there is a meaningful ceiling: the same membrane-disrupting mechanism that makes LL-37 effective against bacteria becomes cytotoxic to mammalian cells at high concentrations. This makes pushing toward the high end of the range a different kind of risk than with many other research peptides, and it reinforces why slow titration is not optional. Second, some protocols use a 5-days-on, 2-days-off pattern rather than true daily dosing, which reduces cumulative immune exposure across the week.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type, your delivery route, and your experience with immune-modulating peptides and builds your LL-37 protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take LL-37?

For subcutaneous injection, the most commonly referenced pattern is once daily. This frequency reflects the reality that LL-37's immune activation is not instantaneous and its effects build with consistent exposure rather than peaking sharply after each dose.

A meaningful subset of protocols use a 5-days-on, 2-days-off schedule rather than seven-day dosing. The rationale is to reduce cumulative immune burden across the week, which matters for a peptide that recruits immune cells and triggers cytokine release as part of its mechanism. For people who experience injection site reactions or systemic flu-like symptoms, the two rest days can meaningfully reduce that burden without substantially compromising the cycle's overall effect.

Physician-supervised protocols sometimes use an even lower frequency, with administration two to three times per week. This approach typically appears in contexts where the goal is chronic condition management and the practitioner is calibrating immune exposure carefully over a longer timeframe.

Timing within the day follows one consistent principle: morning administration is preferred, tied to immune system circadian rhythms, which are more active during waking hours. Consistency matters more than the specific clock hour. A user who doses at the same time each day will see more predictable results than one who varies timing substantially.

For topical application in wound healing, the timing framework is different: dosing is applied directly to the wound site according to the specific clinical protocol being followed, rather than at a systemic injection schedule. The two delivery routes run on separate timing logic.

Loading and Maintenance Phases

LL-37 does not use a conventional structure where a loading dose is set higher than the subsequent maintenance dose. The dose stays consistent with what is tolerated at each stage, and what changes is that the tolerated dose itself rises incrementally across the early weeks. Think of it like adjusting a thermostat one degree at a time: you are not starting hot, you are working up to comfortable. The titration period functions as the loading phase in practical terms, even though it does not involve a distinct elevated starting dose.

In the most widely referenced approach, the first week or two begins at a conservative daily level, establishing that the compound is tolerated before any increase. Each subsequent week, the dose steps up by a fixed increment. By mid-cycle, most people following this approach are at a level that produces the functional immune effect they are targeting. The later weeks of the cycle, once that level is reached, represent the closest thing this protocol has to a maintenance phase. The dose at this stage has not jumped higher; it has arrived at a place the individual worked up to through consistent titration.

A second structure replaces gradual titration with fixed-dose blocks separated by washout periods. In this approach, the dose is set at a consistent level for a block of several weeks, dosing then stops entirely for a washout period, and a second dose block follows. This structure reflects the same underlying logic of managing immune exposure carefully over time.

For topical application, the loading and maintenance concept does not apply in the same way. Clinical data supports topical use at a defined concentration range for cycles up to approximately four weeks, with application directly to the wound site and no titration period.

One important consideration across all phase structures: treat the first weeks of the cycle as a genuine observation period. LL-37 can produce meaningful immune activation even at the starting level. If significant side effects appear early, the titration schedule adjusts to that reality rather than pressing forward on a predetermined timeline.

Off-Cycle Considerations

Taking a break from LL-37 after an on-cycle period is not optional in the way it might be debatable with some other peptides. The rationale is specific: continuous exposure to a compound that activates innate immune pathways can lead to receptor desensitization, where the immune system progressively dampens its response to the peptide's signal. A structured break allows the immune system to return to baseline and restores the compound's effectiveness for the next cycle.

The standard off-cycle duration following a typical 4 to 12 week protocol is 2 to 4 weeks. The shorter end applies to brief acute cycles. The longer end applies after more extended use. One well-referenced framework specifies approximately 7 weeks of daily dosing followed by a 4-week washout, designed explicitly around the desensitization concern.

For CIRS and other chronic condition protocols run under clinical supervision, the off-cycle picture is less clearly defined. These longer-term protocols may not follow the same strict on-off rhythm, and cycling structure in those cases is determined by the supervising practitioner based on the patient's ongoing immune response and monitoring.

Symptom recurrence is a pattern some users report when LL-37 use stops, particularly in cases where the compound was providing ongoing antimicrobial activity against a chronic pathogen load. This is not a reason to avoid the off-cycle break, but it is a reason to have a practitioner involved when winding down a longer protocol.

What to Expect Week by Week

LL-37 does not follow a predictable, uniform week-by-week progression. Outcomes depend heavily on the goal, the individual's baseline immune state, whether a Herxheimer-type reaction occurs, and how the titration is managed. With that context established, here is what use tends to show across a cycle.

• Week 1 to 2: The first week is primarily about establishing tolerability. Injection site reactions, low-grade flu-like symptoms, and fatigue are the most commonly reported early experiences. Some users note gut shifts within the first few days, including changes in cravings and digestion, particularly in SIBO-related protocols. A subset of users experience a notable immune activation response during this period, sometimes described as a Herxheimer-type reaction. Worsened symptoms in inflammatory conditions have also been reported early, including in users with interstitial cystitis and joint-related issues.
• Week 3 to 4: For people tolerating the protocol well, the dose is meaningfully higher than the starting level and the immune effect is more pronounced. Users on acute protocols targeting infection or gut pathogens sometimes see their most significant shifts here. Others report a lag, with limited noticeable change until later in the cycle.
• Week 5 to 8: In longer titration-based protocols, this is when the effective level is reached for most people. Users who have navigated the early immune activation period without discontinuing often report stabilization of side effects alongside more consistent functional changes.
• Beyond 8 weeks: Relevant primarily for CIRS and chronic condition protocols under clinical supervision. Community reports suggest incremental shifts over months of use, though results are highly variable and a proportion of users discontinue due to side effects outweighing perceived benefit.

When an LL-37 protocol goes well, the arc looks something like this: a challenging first few weeks where the immune system responds visibly, followed by gradual stabilization as the body adjusts, then a period of more consistent functional effect as the dose reaches the right level. For gut-focused use, users who stay consistent through the early immune activation period frequently report meaningful reductions in pathogen-related symptoms, reduced bloating, and improved gut tolerability by the mid-cycle point. These are commonly reported patterns, not guarantees, and individual results vary by goal, dose, route, and consistency.

Common Protocol Mistakes

Starting at too high a dose. The most consequential mistake with LL-37 is skipping the gradual titration and beginning at a level the body has not been prepared for. At high concentrations, LL-37 can cause immune overstimulation and is cytotoxic to the neutrophils central to its own mechanism. The titration structure is not a cautious suggestion; it is how the protocol is designed to protect the person running it.

Pushing through severe early reactions. A moderate Herxheimer-type reaction during the first two weeks is an expected possibility. Severe worsening of symptoms, intense neurological effects, or signs of systemic immune overactivation are not signals to push through. They are signals to pause, reduce the dose, and consult a practitioner.

Inconsistent timing and missed doses. LL-37's effects build with consistent immune activation across the cycle. Erratic dosing patterns or substantially varying the time of administration reduces the protocol's coherence and increases the unpredictability of immune responses.

Not rotating injection sites. Subcutaneous injection of LL-37 reliably produces local immune activation at the injection site. Dosing repeatedly at the same location leads to cumulative local irritation and worsening reactions. Rotation across the abdomen, thighs, and upper arm is part of the protocol's mechanics, not optional.

Improper reconstitution and sourcing. Improper reconstitution degrades the peptide and changes both its effectiveness and safety profile. Source from suppliers with verified manufacturing standards, independent testing, and confirmed sterility assurance. Unverifiable sources introduce contamination risk, concentration inaccuracies, and mislabeling that cannot be detected without regulated manufacturing controls.

Not cycling off. Running LL-37 continuously without a structured break leads to immune desensitization and reduces the compound's effectiveness over time. The off-cycle break is built into the protocol for a functional reason.

LL-37 is not FDA-approved for human therapeutic use, and the FDA has formally cautioned against compounded preparations of the compound, citing insufficient safety data for human administration. Athletes subject to testing should confirm current WADA status before use, as international regulatory guidance for LL-37 is not fully defined in available sources.

Frequently Asked Questions

How long is a typical LL-37 cycle?

Most LL-37 protocols run between 4 and 12 weeks on-cycle, depending on the goal. Acute applications like infection support or wound healing tend toward the shorter end, while chronic condition protocols may run toward 12 weeks or longer under clinical supervision. Individual cycle length is set based on goal and response, which is what the MyPeptidePal Protocol Creator personalizes for you.

How often do you take LL-37?

Once daily subcutaneous injection is the most commonly referenced frequency. A 5-days-on, 2-days-off pattern is a widely used alternative that reduces cumulative immune exposure across the week. Physician-supervised protocols sometimes use two to three times per week for chronic condition management.

Does LL-37 need a loading phase?

Not in the conventional sense. LL-37 protocols use a gradual titration structure rather than a distinct loading phase, with the dose starting conservatively and increasing incrementally each week. The titration period functions as the practical equivalent of a loading phase, building toward the level that produces a noticeable immune effect rather than front-loading a higher dose.

Do you need to cycle off LL-37?

Yes, and this is one of the more important structural elements of the protocol. Continuous use without a break leads to immune desensitization, where the immune system progressively reduces its response to the peptide's signal. A break of 2 to 4 weeks after an on-cycle period allows the immune system to return to baseline and restores the compound's effectiveness for a subsequent cycle.

Who should not use LL-37?

People with an active malignancy, particularly breast, ovarian, or lung cancer, should not use LL-37, as research points to pro-tumorigenic activity in those cancer contexts. Individuals with systemic autoimmune conditions such as lupus, psoriasis, or rheumatoid arthritis face a meaningful risk of immune flare. Pregnancy and breastfeeding are also contraindications, as reproductive safety data does not exist for this compound.

Can LL-37 be used topically?

Yes, and topical application has stronger clinical backing than subcutaneous injection for wound healing specifically. Clinical data supports topical use at defined concentration ranges for cycles of up to approximately four weeks. The topical and injectable routes operate on entirely different dose and timing frameworks and should not be treated as interchangeable.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for LL-37 in one place.